The effect of p22-PHOX (CYBA) polymorphisms on premature coronary artery disease (≤ 40 years of age)
暂无分享,去创建一个
G. Maurer | K. Huber | J. Wojta | R. Sunder-Plassmann | C. Mannhalter | M. Schillinger | H. Blessberger | G. Goliasch | Ioannis Tentzeris | F. Wiesbauer | A. Grafl | E. Ponweiser
[1] G. Maurer,et al. Elevated risk of myocardial infarction in very young immigrants from former Yugoslavia , 2009, European Journal of Epidemiology.
[2] O. Wagner,et al. Familial-combined hyperlipidaemia in very young myocardial infarction survivors (< or =40 years of age). , 2009, European heart journal.
[3] A. Castelnuovo,et al. The C242T polymorphism of the p22phox component of NAD (P)H oxidase and vascular risk , 2008, Thrombosis and Haemostasis.
[4] Fred S Apple,et al. Universal definition of myocardial infarction. , 2007, Journal of the American College of Cardiology.
[5] L. Tavazzi,et al. Metabolic syndrome and risk of cardiovascular events after myocardial infarction. , 2005, Journal of the American College of Cardiology.
[6] Hua Tang,et al. Inactivation of Src Family Tyrosine Kinases by Reactive Oxygen Species in Vivo* , 2005, Journal of Biological Chemistry.
[7] R. de Caterina,et al. Oxidative stress and cardiovascular risk: the role of vascular NAD(P)H oxidase and its genetic variants , 2005, European journal of clinical investigation.
[8] A. Cayuela,et al. Long-term prognosis of patients having acute myocardial infarction when =40 years of age. , 2004, The American journal of cardiology.
[9] J. Díez,et al. Functional Effect of the p22phox −930A/G Polymorphism on p22phox Expression and NADPH Oxidase Activity in Hypertension , 2004, Hypertension.
[10] L. Becker. New concepts in reactive oxygen species and cardiovascular reperfusion physiology. , 2004, Cardiovascular research.
[11] J. Paramo,et al. Preliminary characterisation of the promoter of the human p22phox gene: identification of a new polymorphism associated with hypertension , 2003, FEBS letters.
[12] T. Miyatsuka,et al. Association of NAD(P)H oxidase p22 phox gene variation with advanced carotid atherosclerosis in Japanese type 2 diabetes. , 2003, Diabetes care.
[13] G. Zalba,et al. Polymorphisms and Promoter Overactivity of the p22 phox Gene in Vascular Smooth Muscle Cells From Spontaneously Hypertensive Rats , 2001, Circulation research.
[14] K. Channon,et al. Functional Effect of the C242T Polymorphism in the NAD(P)H Oxidase p22phox Gene on Vascular Superoxide Production in Atherosclerosis , 2000, Circulation.
[15] S. Zahler,et al. Endothelial preconditioning by transient oxidative stress reduces inflammatory responses of cultured endothelial cells to TNF‐α , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[16] D. Sanghera,et al. The p22 phox polymorphism C242T is not associated with CHD risk in Asian Indians and Chinese , 1999, European journal of clinical investigation.
[17] A. Quyyumi,et al. Relationship of the C242T p22phox gene polymorphism to angiographic coronary artery disease and endothelial function. , 1999, American journal of medical genetics.
[18] Cai,et al. NADH/NADPH oxidase p22phox C242T polymorphism and coronary artery disease in the Australian population , 1999, European journal of clinical investigation.
[19] A. Gardemann,et al. The p22 phox A640G gene polymorphism but not the C242T gene variation is associated with coronary heart disease in younger individuals. , 1999, Atherosclerosis.
[20] K. Kanazawa,et al. Polymorphism of the NADH/NADPH oxidase p22 phox gene in patients with coronary artery disease. , 1998, Circulation.
[21] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[22] J. Hill,et al. Myocardial infarction in the young and in women. , 1989, Cardiovascular clinics.
[23] W D Dupont,et al. Power calculations for matched case-control studies. , 1988, Biometrics.